Common side effects of Ozempic include gastrointestinal issues such as nausea, vomiting, diarrhea and constipation
Based on the typical UK regulatory pathway, the most realistic timeline is: Late 2026 / early 2027: Eli Lilly expected to submit regulatory filings to the FDA and MHRA following completion of the remaining TRIUMPH Phase 3 readouts Late 2027 to mid-2028: Possible MHRA marketing authorisation, allowing private UK prescribing 2028 to 2029 onwards: Possible NHS availability following a NICE technology appraisal and NHS commissioning decisions Timelines may differ across the four UK nations, as Scotland, Wales, and Northern Ireland assess medicines separately through the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively
The results of subgroup analysis of whether the lifestyle intervention was sustained contrast with those of previous studies which have emphasized the importance of regular exercise for weight loss maintenance [52]
Slowed gastric emptying Helping prolong the feeling of fullness
[26] [27] Ultimately, treatment decisions should be made collaboratively, based on current evidence, regulatory approvals, and individualised assessment of benefits and risks
Saremi, H.J.L
